Enucleation for Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors Larger than 2 Centimeters Is Associated with Equivalent Morbidity and Survival Compared to Smaller Tumors: A Multi-Institutional Study.

MLA

Karam, Elias, et al. “Enucleation for Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors Larger than 2 Centimeters Is Associated with Equivalent Morbidity and Survival Compared to Smaller Tumors: A Multi-Institutional Study.” Neuroendocrinology, vol. 114, no. 11, Nov. 2024, pp. 1034–44. EBSCOhost, https://doi.org/10.1159/000541078.

APA

Karam, E., Nassar, A., Elkurdi, S., Péré, G., Freville, T., Wasielewski, E., Palen, A., Périnel, J., Lifante, J.-C., Lermite, E., Marchese, U., Adham, M., Turrini, O., Sulpice, L., Régenet, N., Carrère, N., Gaujoux, S., Pattou, F., & Sauvanet, A. (2024). Enucleation for Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors Larger than 2 Centimeters Is Associated with Equivalent Morbidity and Survival Compared to Smaller Tumors: A Multi-Institutional Study. Neuroendocrinology, 114(11), 1034–1044. https://doi.org/10.1159/000541078

Chicago

Karam, Elias, Alexandra Nassar, Sara Elkurdi, Guillaume Péré, Thomas Freville, Edouard Wasielewski, Anaïs Palen, et al. 2024. “Enucleation for Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors Larger than 2 Centimeters Is Associated with Equivalent Morbidity and Survival Compared to Smaller Tumors: A Multi-Institutional Study.” Neuroendocrinology 114 (11): 1034–44. doi:10.1159/000541078.